Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)

China flag China · Delayed Price · Currency is CNY
5.04
-0.16 (-3.08%)
Jul 30, 2026, 3:00 PM CST
Market Cap3.66B -15.4%
Revenue (ttm)358.90M +1.7%
Net Income-171.66M
EPS-0.24
Shares Out 703.54M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume28,676,800
Open5.20
Previous Close5.20
Day's Range4.99 - 5.30
52-Week Range4.01 - 8.40
Beta0.17
Analystsn/a
Price Targetn/a
Earnings DateAug 15, 2026

About SHA:603669

Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Pharmaceutical Group Co.,Ltd. was founded in 2003 and is based in Shannan, China. [Read more]

Sector Healthcare
Founded 2003
Employees 284
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603669
Full Company Profile

Financial Performance

In 2025, SHA:603669's revenue was 322.48 million, a decrease of -15.09% compared to the previous year's 379.78 million. Losses were -193.24 million, 47.8% more than in 2024.

Financial Statements